Fornix Biosciences N.V.
Records under this name other than patents Fornix Biosciences N.V. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 6 of 6 · Back to Fornix Biosciences N.V.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,056,511 | Inhibition of Protein Binding to Mast Cells Formerly held Lapsed on the fee record Ended Jun 6, 2018 · High confidence | Lapsed on the fee record | Ended Jun 6, 2018 | High confidence |
| US 6,960,565 | Compound for inhibiting the influx of polymorphonuclear leukocytes (PMNS) in a tissue, its selection, pharmaceutical compositions and use Lapsed on the fee record Ended Nov 1, 2013 · USPTO record | Lapsed on the fee record | Ended Nov 1, 2013 | USPTO record |
| US 6,310,041 | Synthetic complementary peptides and ophthalmologic uses thereof Lapsed on the fee record Ended Oct 30, 2013 · USPTO record | Lapsed on the fee record | Ended Oct 30, 2013 | USPTO record |
| US 7,410,806 | Compound for inhibiting the influx of polymorphonuclear leukocytes (PMNs) in a tissue, its selection, pharmaceutical compositions and use Lapsed on the fee record Ended Aug 12, 2012 · USPTO record | Lapsed on the fee record | Ended Aug 12, 2012 | USPTO record |
| US 6,762,166 | Synthetic complementary peptides and ophthalmologic uses thereof Lapsed on the fee record Ended Jul 13, 2012 · USPTO record | Lapsed on the fee record | Ended Jul 13, 2012 | USPTO record |
| US 7,223,740 | Vectors for enhanced expression of VEGF for atrial disease treatment Lapsed on the fee record Ended May 29, 2011 · USPTO record | Lapsed on the fee record | Ended May 29, 2011 | USPTO record |